Wolfgang Miesbach: Cognitive Impairment in aPL-Positive Patients
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Cognitive impairment in aPL-positive patients.
An important presentation by Gustavo Balbi and colleagues on the real-world recognition and management of cognitive impairment in patients with antiphospholipid antibodies (aPL).
Clinicians most frequently associated aPL with depression, anxiety, impaired attention, slower processing speed, and memory or executive dysfunction.
Yet routine cognitive screening remains uncommon – particularly in patients without stroke and TIA or overt symptoms.
Stronger collaboration between APS specialists, cognitive neurologists, and neuropsychologists is urgently needed to improve recognition, assessment, and care.”
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Nov 9, 2026, 09:29Veronica Sanchez: A Framework for Woman’s Health
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause